Biomarin Pharmaceutical INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
BioMarin Pharmaceutical Inc. achieved $3.2 billion in total revenues in 2025, driven by VOXZOGO expansion, while strategically withdrawing ROCTAVIAN from the market and pursuing significant acquisitions to bolster its rare disease portfolio.
NASDAQ
BioMarin achieved $2.9 billion in total revenues in 2024, fueled by VOXZOGO's growth and pipeline advancements, while implementing a new corporate strategy focused on innovation, growth, and value commitment.
NASDAQ
10-K: BioMarin Pharmaceutical Inc. Reports 2023 Financial Results, Highlights Strategic Advancements
BioMarin Pharmaceutical Inc. achieved $2.4 billion in total revenues in 2023, driven by VOXZOGO expansion and key pipeline advancements, including FDA approvals for VOXZOGO and ROCTAVIAN.